News

ReShape Lifesciences Achieves Patent Milestone for Innovative Technology

ReShape Lifesciences Achieves Patent Milestone for Innovative Technology

ReShape Lifesciences Secures Patent Approval for Diabetes Technology

IRVINE, Calif. — ReShape Lifesciences (NASDAQ: RSLS), recognized as a leader in physician-led weight loss and metabolic health solutions, has made a significant step forward by obtaining a Notice of Allowance from the U.S. Patent and Trademark Office for its innovative diabetes neuromodulation technology. This milestone comes with the patent application titled, “Simultaneous Multi-Site Vagus Nerve Modulation for Improved Glycemic Control System and Methods.” Upon issuance, the patent will remain effective until 2039, enhancing protection for this groundbreaking technology aimed at combatting Type 2 diabetes.

Understanding the Diabetes Neuromodulation Technology

The recently allowed patent bolsters ReShape's ongoing efforts to revolutionize diabetes treatment. By utilizing its proprietary vagus nerve block (vBloc™), the Diabetes Neuromodulation system leverages vagus nerve stimulation to enhance glycemic control, significantly impacting the lives of individuals managing Type 2 diabetes, a condition widely associated with obesity. Paul F. Hickey, the President and Chief Executive Officer of ReShape Lifesciences, emphasized the potential of this technology to minimize reliance on medications via a personalized treatment approach. This innovation aims not only to streamline glucose management but also to reduce associated healthcare costs.

The Science Behind the Therapy

Leading the research efforts at ReShape, Dr. Jonathan Waataja highlighted the critical role of effective blood glucose regulation in managing Type 2 diabetes, which remains a pressing global health challenge. The Diabetes Neuromodulation technology functions by precisely modulating both vagal block and nerve stimulation targeting the liver and pancreas. Pre-clinical trials indicate promising results, with improved glycemic control demonstrated in studies involving both Zucker rats and specially treated swine models. The successful completion of the pre-clinical development phase marks a pivotal milestone, showcasing the potential of bioelectronics in personalizing diabetes management.

The Future of Personalized Medicine

The ReShape Diabetes Neuromodulation Device (previously known as Diabetes Bloc-Stim Neuromodulation™ (DBSN™)) introduces a state-of-the-art, minimally invasive therapy designed to deliver bio-electronic neuromodulation to the vagus nerve branches that strategically influence plasma glucose levels. This device stimulates the pancreas' vagus celiac fibers to induce insulin release while effectively curbing glucose output from the liver through an adjustable electrical blockade. This innovative approach is seen as a definitive stride toward personalized medicine, offering an advantage over traditional methods such as standalone nerve stimulation or nerve ligation, both of which can lead to undesirable side effects.

About ReShape Lifesciences

ReShape Lifesciences stands out as America's premier entity focused on weight loss and metabolic health solutions. The organization boasts an extensive portfolio of validated products and services addressing obesity and metabolic disorders. Its offerings include FDA-approved products such as the Lap-Band® and Lap-Band® 2.0 Flex Systems, designed for minimally invasive, long-term obesity treatment alternatives. The Obalon® balloon technology provides a unique, non-surgical weight loss solution with a swallowable, gas-filled intra-gastric balloon, symbolizing innovation in the weight management landscape.

Strategic Developments and Future Plans

In a noteworthy move, ReShape recently engaged in an asset purchase agreement with Biorad Medisys, Pvt. Ltd. This agreement entails the transfer of most of ReShape's assets, including the Lap-Band® System, Obalon® Gastric Balloon System, and the DBSN™ system, to Biorad, excluding cash assets. The impending closure of this transaction is set to transition ownership of the DBSN™ system to Biorad, further aligning with ReShape's strategic objectives.

Frequently Asked Questions

What is the significance of the patent ReShape Lifesciences received?

The patent allows ReShape Lifesciences to protect its innovative Diabetes Neuromodulation technology, vital for improved treatment of Type 2 diabetes.

How does the Diabetes Neuromodulation Device work?

This device utilizes bio-electronic neuromodulation targeted at vagus nerve branches to regulate insulin production and blood glucose levels.

What are the benefits of this technology for diabetes treatment?

The technology aims to reduce dependence on medication, lower healthcare costs, and improve overall glycemic control.

Can you explain the collaboration with Biorad Medisys?

ReShape has agreed to sell significant assets, including various systems, to Biorad, marking a strategic partnership in the healthcare sector.

Where can I find more information about ReShape Lifesciences?

Additional information is available on ReShape Lifesciences' official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Silvi's Expansion Push: New Terminal in Wilmington

Updated Category News Views 89

Silvi's Latest Bet on the Southeast You know, sometimes you get a gut feeling that a company is rolling out chess moves instead of checkers. That’s what Silvi Materials is up to with their new project in Wilmington. It’s not just some fancy cement terminal—it’s a calculated expansion into the heart of the Southeast construction market. The Port of Wilmington’s...

Continue Reading
NeuroPace Faces Investigation After Revenue Forecast Cut

Updated Category News Views 35

NeuroPace Revenue Drama: A Blow to Investor Confidence How the mighty have stumbled—or so it feels to the folks who put their bucks into NeuroPace, Inc. (NASDAQ: NPCE). It's tough to swallow: they cut their 2026 revenue forecast from a hopeful $99.5-$101.5 million to a sobering $91-$92 million. Just one quarter apart those projections are, like a cruel twist of fate...

Continue Reading
Biotech Hit or Miss: Trials and Tribulations

Updated Category News Views 96

Biotech's Roller Coaster: Triumphs and Setbacks Ah, the biotech sector—it's a bit like jumping on a bull, ain't it? You barely hang on when the beast bucks. Monday's market action was downright wild. The S&P 500 didn't have a party, tumbling 1.92%, and the Nasdaq wasn't any friendlier, plummeting 2.49%. Yet, inside this storm, we see some biotech names either catching...

Continue Reading
Pollo AI Unveils York AI: Automating Social Growth

Updated Category News Views 302

York AI Debuts as the New Kid on the Block Amid the hustle and bustle of a tech-savvy Singapore, Pollo AI’s latest offering, York AI, sashays onto the scene with the promise of putting social media growth on cruise control. We're talking about a digital sidekick that seems to know your online persona better than you do. It’s tailored for everyone from the small-time...

Continue Reading
LongueVue Capital: Betting Big on Sports & Entertainment

Updated Category News Views 90

LongueVue Capital's Bold Move You don’t always hear about private equity firms diving head-first into the sports and entertainment sector, but LongueVue Capital (LVC) is doing just that. This New Orleans-based firm is shifting its gears and setting sights on founder-owned ventures crucial to these industries. They’re asking the key question: Why focus on just the...

Continue Reading
Pine Tree Bets Big on Tulsa Hills Shopping Center

Updated Category News Views 188

Pine Tree's Latest Move in Retail Real Estate Ya ever watch a company make a move so aligned with its playbook that it feels like a script straight outta the boardroom? That's Pine Tree with its recent snag of Tulsa Hills Shopping Center for a cool $108 million. This ain't just any retail spot; it's a bustling hub nestled within the posh outskirts of Jenks, Oklahoma....

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 100

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Cardio Partners Hits a Million Milestone with Red Cross

Updated Category News Views 57

One Million Trained, One Million Prepared Ah, a million sounds like just another number, doesn't it? But when someone's life hangs in the balance, those are a million folks ready to jump in and act. Cardio Partners has hit this mighty milestone in CPR, AED, and First Aid training, gaining a pat on the back from none other than the American Red Cross. It's a testament,...

Continue Reading
Daqo New Energy Faces Key Investor Meeting in December

Updated Category News Views 103

Spotlight on December's Agenda for Daqo Shareholders Who'd have thought we'd be looking at another year end with the same burning energy interests? Daqo New Energy Corp. (NYSE: DQ) is setting up for its annual general meeting (AGM) dated December 10, 2026. Mark your calendars, because these gatherings can be more than just straightforward affairs; sometimes they reveal...

Continue Reading
LinkedIn Shines: Brands Face Social Media Slump

Updated Category News Views 77

LinkedIn: The Unsung Hero in Social Platforms In a world where social media seems to be as unpredictable as the stock market, LinkedIn is surprisingly holding the line. According to Vista Social's 2027 report, LinkedIn proudly boasts the highest median engagement rate among brand pages at 5.8%. Now, in the wild west of social media, where reach is getting tougher to snag,...

Continue Reading

Top 5 Most Recently Viewed Articles

FMC Corporation Faces Class Action Suit for Securities Fraud

Updated Category News Views 229

FMC Corporation Faces Class Action Suit for Securities Fraud The Rosen Law Firm, a prominent global firm advocating for investor rights, has initiated a class action lawsuit on behalf of purchasers of FMC Corporation (NYSE: FMC) securities. This lawsuit encompasses transactions made between specific dates in 2023 and 2025, referred to as the "Class Period." A prior...

Continue Reading
Verde Resources' BioAsphalt™ Demonstrates Carbon Sequestration Potential

Updated Category News Views 210

Verde's Innovative BioAsphalt™ Delivers Promising Validation Verde Resources Inc. (OTCQB: VRDR), a pioneering entity focused on sustainable infrastructure solutions, is proud to announce remarkable initial validation of its Biochar-Asphalt technology. This breakthrough was showcased at a renowned test track, highlighting the material's capabilities in sequestering...

Continue Reading
REGENXBIO Conference Call to Reveal Q3 Financial Insights

Updated Category News Views 71

REGENXBIO to Host a Key Conference Call REGENXBIO Inc. (NASDAQ: RGNX) has announced an important conference call aimed at discussing its financial results for the recently concluded third quarter. The call is scheduled for a weekday afternoon, at 4:30 p.m. ET. Participants can expect a thorough discussion on the financial performance that was achieved by REGENXBIO during...

Continue Reading
AppFolio Celebrates Ranking Among Fortune's Future 50 List

Updated Category News Views 256

AppFolio's Recent Achievements Highlight Company Growth AppFolio, the technology leader transforming the real estate sector, recently announced exciting news regarding its recognition by Fortune magazine. The company has been honored with a spot on Fortune's prestigious Future 50 and Best Workplaces in Technology lists. This acknowledgment underlines AppFolio's commitment...

Continue Reading
NDBN Teams Up with CareSource to Combat Diaper Shortage

Updated Category News Views 91

Introduction to the New Partnership The National Diaper Bank Network (NDBN) has formed a significant partnership with CareSource, a managed care organization renowned for its commitment to health and wellness. This collaboration aims to alleviate diaper need across the nation, providing essential support to families facing financial challenges. The Scope of Diaper Need in...

Continue Reading